@article{Hajati_Talebian_Babahajian_Daneshkhah_Ghaderi_2022, title={Association of Serum Leptin with Prognostic Factors in Breast Cancer}, volume={17}, url={https://knepublishing.com/index.php/SJMS/article/view/10681}, DOI={10.18502/sjms.v17i1.10681}, abstractNote={<p><strong>Background:</strong> Nowadays, cytokines such as Leptin and adiponectin are introduced as prognostic factors which, according to some studies, are also associated with body mass index. This study aimed to determine serum leptin level and its relationship with prognostic factors in breast cancer patients.</p> <p><strong>Methods:</strong> This case–control study was conducted in the oncology department of Tohid Hospital, Sanandaj, Iran, between 2019 and 2020. Hundred new cases of breast cancer patients with histological evidence were enrolled in this study. Additionally, 100 age- and BMI-matched healthy individuals were recruited as the control group. The serum leptin level was measured using the ELISA method.</p> <p><strong>Results:</strong> Serum leptin levels were significantly higher in breast cancer patients compared to the control group (21.68 ± 9.16 vs 11.89 ± 4.45; <em>p</em> &lt; 0.001). There was no significant relationship between plasma leptin levels with ER, PR, and HER2 expressions (<em>p</em> &gt; 0.05). Also, no significant associations were noted between leptin levels and grading and disease staging (<em>p</em> &gt; 0.05).</p> <p><strong>Conclusion:</strong> The study found that leptin is higher in breast cancer patients than in healthy individuals, however, it did not prove that leptin is a predictive or prognostic factor.</p&gt;}, number={1}, journal={Sudan Journal of Medical Sciences (SJMS)}, author={Hajati, Amirreza and Talebian, Farshad and Babahajian, Asrin and Daneshkhah, Nasrin and Ghaderi, Bayazid}, year={2022}, month={Mar.}, pages={4-14} }